Cagrilintide

Cagrilinitide (or “Cagri”) is a long-acting, lipidated, albumin-binding amylin agonist that targets both amylin and calcitonin receptors. It is used in the treatment of obesity, either on its own or in combination with GLP-1 receptor agonists.

Amylin is co-secreted with insulin from pancreatic beta cells and regulates appetite, satiety, gastric emptying, and glucose control.

Combining Cagrilinitide with a GLP-1 such as Semaglutide has a synergistic effect, amplifying weight loss beyond what either peptide achieves independently. Other benefits include improved circulation, reduced blood pressure, enhanced bone-building activity, and vasodilation.

Outcomes

• 6–10% body weight loss at 26 weeks (Cagrilinitide alone)
• 23–24.4% body weight loss at 68 weeks (combined with Semaglutide)
• Synergistic effect: up to 8% more weight loss vs. Semaglutide alone

Possible Side Effects

• Injection site reaction (redness, swelling, itching, hives)
• Nausea
• Vomiting
• Constipation
• Fatigue
• Headache
• Diarrhea
• Heartburn
• Gallbladder stones (rare)